SPAG5, the upstream protein of Wnt and the target of curcumin, inhibits hepatocellular carcinoma

Li,Huiyang; Qin,Yanfei; Huang,Yiran; Wang,Jinquan; Ren,Biqiong

doi:10.3892/or.2023.8609

SPAG5, the upstream protein of Wnt and the target of curcumin, inhibits hepatocellular carcinoma

Authors:
- Huiyang Li
- Yanfei Qin
- Yiran Huang
- Jinquan Wang
- Biqiong Ren
View Affiliations

Affiliations: Clinical Medical College of Hunan University of Chinese Medicine, Changsha, Hunan 410007, P.R. China
Published online on: August 3, 2023 https://doi.org/10.3892/or.2023.8609
Article Number: 172
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The inhibitory role of curcumin on sperm-associated antigen 5 (SPAG5) and its effects on the cancer‑related Wnt classical signaling pathway has been previously demonstrated. Nevertheless, research on the modulatory role of curcumin on the Wnt signaling pathway by acting on SPAG5 has yet to be reported. The activation of the Wnt/β‑catenin pathway is frequently observed in patients suffering from hepatocellular carcinoma (HCC), suggesting that small molecular drugs that target Wnt could present a promising therapeutic strategy. However, these drugs often result in substantial side effects. In the present study, the presence of SPAG5 in the cancer tissues of patients with HCC and cell lines was validated using immunohistochemistry, cellular immunofluorescence, reverse transcription‑quantitative polymerase chain reaction, and western blot analyses. Subsequently, the effect of SPAG5 and the regulatory role of curcumin on SPAG5 and the Wnt/β‑catenin pathway were examined using cell function tests, flow cytometry, and western blotting. Techniques of gene knockout and overexpression were employed. The findings revealed a significant overexpression of SPAG5 in the cancer tissues of patients with HCC. Both the mRNA and protein levels of SPAG5 in Huh7 and HCCLM3 cell lines were markedly elevated. Treatment with curcumin led to a decrease in SPAG5 expression, while also inhibiting cell migration and promoting apoptosis. Additionally, suppression of SPAG5 expression resulted in the decreased expression of β‑catenin. Furthermore, curcumin was observed to reduce the expression of cyclin D1 in SPAG5‑overexpressing cell lines. However, the degree of inhibition was diminished once SPAG5 expression was silenced. These initial findings indicate that SPAG5 may function as an upstream regulatory protein of the Wnt/β‑catenin pathway, hence offering a potential alternative target for HCC. Moreover, as curcumin has the capacity to inhibit Wnt via suppressing SPAG5, it could potentially serve as a natural drug component for early intervention and treatment of HCC.

View Figures

View References

1	Mejia JC and Pasko J: Primary liver cancers: Intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Surg Clin North Am. 100:535–549. 2020. View Article : Google Scholar : PubMed/NCBI
2	Chidambaranathan-Reghupaty S, Fisher PB and Sarkar D: Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 149:1–61. 2021. View Article : Google Scholar : PubMed/NCBI
3	Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C and Chen W: Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer. 148:1051–1065. 2021. View Article : Google Scholar : PubMed/NCBI
4	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
5	Thein KH, Kleylein-Sohn J, Nigg EA and Gruneberg U: Astrin is required for the maintenance of sister chromatid cohesion and centrosome integrity. J Cell Biol. 178:345–354. 2007. View Article : Google Scholar : PubMed/NCBI
6	Buechler S: Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer. 9:2432009. View Article : Google Scholar : PubMed/NCBI
7	Välk K, Vooder T, Kolde R, Reintam MA, Petzold C, Vilo J and Metspalu A: Gene expression profiles of non-small cell lung cancer: Survival prediction and new biomarkers. Oncology. 79:283–292. 2010. View Article : Google Scholar : PubMed/NCBI
8	Yang YF, Zhang MF, Tian QH, Fu J, Yang X, Zhang CZ and Yang H: SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 17:1172018. View Article : Google Scholar : PubMed/NCBI
9	Zhang H, Li S, Yang X, Qiao B, Zhang Z and Xu Y: miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
10	Li M, Li A, Zhou S, Lv H and Yang W: SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. J Hematol Oncol. 12:142019. View Article : Google Scholar : PubMed/NCBI
11	Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, et al: SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: A retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 17:1004–1018. 2016. View Article : Google Scholar : PubMed/NCBI
12	Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH and Zheng M: SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis. 5:e12472014. View Article : Google Scholar : PubMed/NCBI
13	Liu H, Hu J, Wei R, Zhou L, Pan H, Zhu H, Huang M, Luo J and Xu W: SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation. J Exp Clin Cancer Res. 37:2292018. View Article : Google Scholar : PubMed/NCBI
14	Jiang J, Wang J, He X, Ma W, Sun L, Zhou Q, Li M and Yu S: High expression of SPAG5 sustains the malignant growth and invasion of breast cancer cells through the activation of Wnt/β-catenin signalling. Clin Exp Pharmacol Physiol. 46:597–606. 2019. View Article : Google Scholar : PubMed/NCBI
15	Liu JY, Zeng QH, Cao PG, Xie D, Yang F, He LY, Dai YB, Li JJ, Liu XM, Zeng HL, et al: SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival. Oncogene. 37:3937–3952. 2018. View Article : Google Scholar : PubMed/NCBI
16	Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, et al: Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology. 64:2047–2061. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hayat R, Manzoor M and Hussain A: Wnt signaling pathway: A comprehensive review. Cell Biol Int. 46:863–877. 2022. View Article : Google Scholar : PubMed/NCBI
18	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
19	De A: Wnt/Ca2+ signaling pathway: A brief overview. Acta Biochim Biophys Sin (Shanghai). 43:745–756. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kahn M: Can we safely target the WNT pathway? Nat Rev Drug Discov. 13:513–532. 2014. View Article : Google Scholar : PubMed/NCBI
22	Duchartre Y, Kim YM and Kahn M: The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149. 2016. View Article : Google Scholar : PubMed/NCBI
23	Steinhart Z and Angers S: Wnt signaling in development and tissue homeostasis. Development. 145:dev1465892018. View Article : Google Scholar : PubMed/NCBI
24	Tafrihi M and Nakhaei Sistani R: E-Cadherin/β-Catenin Complex: A target for anticancer and antimetastasis plants/plant-derived compounds. Nutr Cancer. 69:702–722. 2017. View Article : Google Scholar : PubMed/NCBI
25	Gupta SC, Patchva S and Aggarwal BB: Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 15:195–218. 2013. View Article : Google Scholar : PubMed/NCBI
26	Udagawa T and Wood M: Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol. 10:369–374. 2010. View Article : Google Scholar : PubMed/NCBI
27	Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP and Khanna KK: Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene. 29:6085–6098. 2010. View Article : Google Scholar : PubMed/NCBI
28	Jin H, Lian N, Zhang F, Chen L, Chen Q, Lu C, Bian M, Shao J, Wu L and Zheng S: Activation of PPARγ/P53 signaling is required for curcumin to induce hepatic stellate cell senescence. Cell Death Dis. 7:e21892016. View Article : Google Scholar : PubMed/NCBI
29	Ashrafizadeh M, Ahmadi Z, Mohamamdinejad R, Yaribeygi H, Serban MC, Orafai HM and Sahebkar A: Curcumin therapeutic modulation of the wnt signaling pathway. Curr Pharm Biotechnol. 21:1006–1015. 2020. View Article : Google Scholar : PubMed/NCBI
30	Vallée A, Lecarpentier Y and Vallée JN: Curcumin: A therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway. J Exp Clin Cancer Res. 38:3232019. View Article : Google Scholar : PubMed/NCBI
31	Patel SS, Acharya A, Ray RS, Agrawal R, Raghuwanshi R and Jain P: Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr. 60:887–939. 2020. View Article : Google Scholar : PubMed/NCBI
32	Ghasemi F, Shafiee M, Banikazemi Z, Pourhanifeh MH, Khanbabaei H, Shamshirian A, Amiri Moghadam S, ArefNezhad R, Sahebkar A, Avan A and Mirzaei H: Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol Res Pract. 215:1525562019. View Article : Google Scholar : PubMed/NCBI
33	Chen W, Chen X, Li S and Ren B: Expression, immune infiltration and clinical significance of SPAG5 in hepatocellular carcinoma: A gene expression-based study. J Gene Med. 22:e31552020. View Article : Google Scholar : PubMed/NCBI
34	Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
35	Zhou M, Zhao K, Yao Y, Yuan Y, Pei R, Wang Y, Chen J, Hu X, Zhou Y, Chen X and Wu C: Productive HBV infection of well-differentiated, hNTCP-expressing human hepatoma-derived (Huh7) cells. Virol Sin. 32:465–475. 2017. View Article : Google Scholar : PubMed/NCBI
36	Li B, Zhang Y, Wu W, Du G, Cai L, Shi H and Chen S: Neovascularization of hepatocellular carcinoma in a nude mouse orthotopic liver cancer model: A morphological study using X-ray in-line phase-contrast imaging. BMC Cancer. 17:732017. View Article : Google Scholar : PubMed/NCBI
37	Ram S, Vizcarra P, Whalen P, Deng S, Painter CL, Jackson-Fisher A, Pirie-Shepherd S, Xia X and Powell EL: Pixelwise H-score: A novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images. PLoS One. 16:e02456382021. View Article : Google Scholar : PubMed/NCBI
38	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI